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Abstract:  
Purpose: To determine whether participants on ACEIs treated with radical radiotherapy with 
neoadjuvant/adjuvant hormonal therapy have less incidence, severity and duration of 
radiation proctitis. 
Methods and Materials: A propensity score analysis of n=817 patients who underwent 
radical radiotherapy with neoadjuvant/adjuvant hormonal therapy as primary line 
management in cohort study during 2009 to 2013 has been conducted. Patients were stratified 
into: (1) hypertensive on ACEIs (as a study group), (2) non-hypertensive not on ACEIs and 
(3) hypertensive not on ACEIs (both as a control group). The incidence, severity and duration 
of proctitis were the main outcome. Chi-square, Mann-Whitney U, ANOVA, risk ratio, 
confidence interval, Kaplan–Meier plots and Log-Rank tests were used. 
Results:  
The mean age of the participants was 68.91 years with a follow-up of 3.38 years. Based on 
disease and age matched comparison there was a statistically significant difference of 
proctitis grading between the three groups 2 (8, n=308) = 72.52, p < 0.001. The Mann-
Whitney U test indicated that grades of proctitis were significantly lower in hypertensive on 
ACEIs group than non-hypertensive not on ACEIs and hypertensive not on ACEIs groups 
(p<0.001). The risk ratio of proctitis in hypertensive on ACEIs group was significantly lower 
than hypertensive not on ACEIs group (RR 0.40, 95% CI, 0.30 – 0.53, p<0.001) and non-
hypertensive not on ACEIs group (RR 0.58, 95% CI, 0.44 – 0.77, p<0.001). Time to event 
analysis revealed that hypertensive on ACEIs group was significantly different comparing to 
the control groups (p<0.0001). Furthermore, hypertensive on ACEIs group has significantly 
faster resolution of proctitis (P<0.0001). 
Conclusion: Patients who were on ACEIs were significantly less likely to have high grade 
proctitis after radical radiotherapy with neoadjuvant/adjuvant hormonal therapy (p < 0.001). 
The intake of ACEIs were significantly associated with reduced risk of radiation induced 
proctitis as well as accelerating its resolution.  
Keywords: Prostatic cancer; Radiotherapy; Proctitis; Angiotensin converting enzyme 
inhibitors, Pneumonitis; Nephritis.  
Introduction: 
Since the introduction of the prostate-specific antigen (PSA) testing in prostate cancer 
screening, more patients are now diagnosed earlier, and subsequently have undergone radical 
treatment (1). One option in clinical management of prostate cancer is radical radiotherapy 
(2, 3). However, proctitis is one of the complications of prostatic radiotherapy and can have a 
profound negative affect on patients’ overall quality of life (4 – 7). The initial step of proctitis 
is cell death and cell depletion leading to loss of the epithelium lining and as a consequence it 
causes oedema and mucosal inflammation which later leads to ulceration and sepsis. By the 
time it spreads to submucosa and provokes a regenerative response which in turn causes 
either normal tissue repair or ulceration, fibrosis and stricturing. Obliteration, fibrosis and 
angiogenesis lead to the clinical manifestations of rectal bleeding, tenesmus, diarrhoea and 
strictures (8 – 11).  
Experimental studies showed that the ACEIs may prevent development of radiation-induced 
injuries in certain tissues (12 – 14). ACEIs are anti-hypertensive drugs that block the enzyme 
and prevent conversion of angiotensin I to angiotensin II which plays an important role in 
controlling the blood pressure. Previous studies have focused on the effect of ACEIs in 
prevention of radiation induced lung toxicity. Four animal studies (12 – 16) conducted 
between 1988 and 2009, have all reported consistent results of the protective effect of the 
ACEIs in lung parenchyma yielded beneficial outcomes in terms of reducing the incidence of 
radiation-induced pneumonitis. In lung cancer patients, there have been four clinical studies 
(14, 17 – 19) conducted between 2000 and 2013. One study (14) reported a beneficial effect 
of ACEIs (n=146) in preventing radiation induced lung injury using multivariate analysis. 
Other studies have not identified any significant association between ACEIs and radiation 
pneumonitis in individuals affected by lung cancer (17 – 19).  
Studies have also investigated the relationship between ACEIs and radiation-induced 
nephritis. To date, ten studies (20 – 29) have been conducted between 1986 and 2014. Most 
studies have reported consistent results in the beneficial association between ACEIs and 
reduced risk of renal toxicity, albeit the majority of these studies (90%) were animal studies. 
Only (29) reported that all ACEIs mitigate radiation nephropathy except fosinopril. 
Elsewhere, (22) did not report any association between ACEIs and reduced risk of radiation-
induced nephritis in a patient population of lung cancer patients.  
Moreover, two animal studies (30, 31) have demonstrated that the intake of ACEIs have 
reduced the prevalence of radiation induced brain injuries, including cognitive impairment 
and optic neuropathy. Other studies have explored the association between ACEIs and 
gastrointestinal (GI) toxicity. Six clinical studies (32 – 37) have been conducted between 
2004 and 2012, and all investigated the effect of hypertension on normal tissue radiation 
induced toxicity. Three of which (32, 34, 37) have consistently reported a beneficial effect of 
the ACEIs on GI tract toxicity. In one animal study, (26) did not find any association between 
the ACEIs and GI tract toxicity.  
To date, there have been a number of studies (animal and human) investigating the potential 
association between ACEIs and its protective effects on reducing the incidence of radiation-
induced injuries in renal, brain, GI tract and pelvic cancer. To the best of our knowledge, no 
study has explored the effect of ACEIs and in men affected by prostate cancer treated by 
radical radiotherapy with neoadjuvant/adjuvant hormonal therapy.  We aimed to evaluate 
whether the concurrent use of ACEIs decrease the incidence, severity and duration of 
radiation induced proctitis in prostatic cancer patients treated by radical radiotherapy. 
Methods and Materials: 
The study had Caldecott Institutional Approval (Caldicott/CSAppGN021211). During   
January 2007 and December 2013, all consecutive patients who underwent radical 
radiotherapy and neoadjuvant/adjuvant hormonal therapy were identified from 
comprehensive clinical databases hosted at one of main cancer centres in the UK. Patients 
were identified from electronic databases through a validated cross linkage methodology as 
described previously by our group (38, 39). Record linkage technique brings together two or 
more records relating to the same individual identified by a common identifier (Community 
Health Index [CHI] number in this series). Cross-linkage of databases enabled demographical 
and clinical data to be securely managed at one centralised database for the purpose of this 
study.   
The database with (CHI) was linked to the following clinical systems: 
(i) WISDOM oncology system (Web Information System for Data Oncology 
Management) which securely stores the following clinical information: clinical 
presentation, PSA, cancer stage, Gleason score, radiotherapy, chemotherapy, 
clinical complications, follow-up and mortality 
(ii) Referral Management System (RMS) which is a primary care system for a 
population of more than 400,000 individuals. Data linkage captured the doses, 
start date of ACEIs and name of medication (38, 39).  
(iii) Multidisciplinary Board Meeting (MDT) records where all men diagnosed with 
prostate cancer are discussed on a weekly basis.   
(iv) Integrated Clinical Environment (ICE) system provides clinicians with diagnostic 
services as a means to electronically order tests and view results. Using the CHI 
number we searched for sequential PSA results. 
(v) Records were searched using Clinical Portal and the In House Surgical 
Information System web and Technology (Insite), these databases host secure 
electronic patient records which systematically captures follow-up history 
including communication between acute and primary care.  
Inclusion criteria were: (I) patients who are newly diagnosed and histologically confirmed 
localized or locally advanced adenocarcinoma of prostate; (II) patients who acquired primary 
radical radiotherapy and neoadjuvant/adjuvant hormonal therapy; (III) patients who received 
a dose  of radiotherapy ranged between 4500cGY – 5700cGY in 20 fraction over 20 to 32 
days; (IV) patients acquired 3D field conformal radiotherapy; (V) patients prescribed ACEIs 
before (at least 6 months) and during the course of prostate radiotherapy; and (VI) patients 
who were on ACEIs combined with other anti-hypertensive medications before (at least 6 
months) and during the course of prostate radiotherapy. Exclusion criteria were: (1) patients 
who received adjuvant radiotherapy following radical prostatectomy; (2) patients with 
missing data including lack of the dose of radiotherapy, tumour stage, Gleason score, PSA or 
no history of follow-up; (3) patients who have radiotherapy only; and (4) haemorrhoids. 
The incidence, severity and duration of all types of radiation induced proctitis were the 
primary study outcome. Radiation induced proctitis was graded according the European 
Organization for Research and Treatment of Cancer (EORTC) and the Radiation Therapy 
Oncology Group (RTOG) grading system of radiation proctitis (40, 41) (supplementary Table 
1). The records were assessed for grading classification by two members of the research team 
(AA and CP) to rate the severity of proctitis for each patient within the study. Inter-rater 
reliability between the observers was assessed using the Kappa statistic (Kappa=0.809 with 
p<0.001) and was found to have substantial agreement (42).  
Patients were stratified according to the ACEIs usage into: group (1) hypertensive on ACEIs 
(as a study group), group (2) non-hypertensive not on ACEIs and group (3) hypertensive not 
on ACEIs (both as a control group). The two control groups (non-hypertensive not on ACEIs 
and hypertensive not on ACEIs) were identified from the same centralised database. The 
hypertensive not on ACEIs group consisted of hypertensive patients that were treated by 
other types of antihypertensive medications including calcium channel, beta or alpha 
blockers. 
In statistical analysis of observation data, propensity score–matching method is an alternative 
statistical technique to randomization which estimates the effect of treatment and reduces the 
bias of confounding variables (43, 44). The propensity score–matched method was used to 
balance any observed covariates between the groups. It was created using disease specific and 
non-disease specific variables including: age, tumour stage, Gleason score, PSA level before 
and co-morbidities. Participants acquiring radiotherapy and neoadjuvant/adjuvant hormonal 
therapy were matched on a one-to-one case base. Matching was accomplished based on the 
closest-neighbour matching (43, 44).  
The three groups were treated in the same cancer centre with neoadjuvant and adjuvant 
hormone therapy and radiotherapy. Each group in the study were treated by three field 
conformal radiotherapy with a median dose of 5400cGY (ranged, 4500cGY – 5700cGY), 20 
fraction (ranged, 19 – 22) and 28 days (ranged, 20 – 32) following UK guidelines (45).  
To compare the contrast in proportions of baseline characteristics between the study and the 
two control groups, 2 was used. The ANOVA, risk ratio (RR) and confidence interval (CL) 
tests were performed using SPSS.21. In follow-up Mann-Whitney U test was used. Using 
Bonferroni adjusted alpha level less than 0.017 was considered to be significant. Time from 
radiotherapy to onset of proctitis was compared between study and control groups using 
Kaplan–Meier plots and Log-Rank test. Furthermore, time from radiotherapy to resolution of 
proctitis was also compared between study and control groups using Kaplan–Meier plots and 
Log-Rank test. 
Results:  
The clinical and demographic characteristics of the study participants are presented in Table 
(2). The total number of patients who underwent 3D radical radiotherapy with 
neoadjuvant/adjuvant hormonal treatment as primary line management in the cohort study 
was 817. Of 817 there were 389 patients with hypertension and 428 non-hypertensive 
patients. Based on the inclusion and exclusion criteria and the propensity score matched 
analysis, n=308 participants were included in this study.   
The overall mean age of the participants in the study was 68.91 (SD, 5.67) years with a 
follow-up of 3.38 (SD, 1.95) years. Of 308 there were n=102 participants in hypertensive on 
ACEIs group with a mean age 68.64 (SD, 5.31) years and follow-up of 3.27 (SD 1.90) years, 
103 participants in hypertensive not on ACEIs group with a mean age 68.61 (SD, 5.59) years 
and follow-up of 3.73 (SD 2.10) years and 103 participants in non-hypertensive not ACEIs 
group with a mean age of 68.49 (SD, 6.11) years and follow-up of 3.15 (SD, 1.82) years. 
The distribution of clinical characteristics in all participants were found as: T1 was found in 
n=22 (7.1%), Gleason score 2 – 6, n=11 (50%), Gleason score 7, n=8 (36.4%) and Gleason 
score 8 – 10 n=3 (13.6%); T2 in n=124 (40.3%), Gleason score 2 – 6 n=22 (17.7%), Gleason 
score 7: n=39 (31.5%) and Gleason score 8 – 10 n=63 (50.8%); and T3 n=162 (52.6%), 
Gleason score 2 – 6 n=8 (4.9%),  Gleason score 7 (3+4) n=38 (23.5%) and Gleason score 7 
(4+3) – 10 n=116 (63.7%). Based on disease and age matched comparison there was a 
statistically significant difference of proctitis grading between the three groups 2 (8, n=308) 
= 72.52, p < 0.001. The Mann-Whitney U test indicated that grades of proctitis were 
significantly lower in hypertensive on ACEIs group (Md = 83.08, n = 102) than non-
hypertensive not on ACEIs group (Md = 122.72, n = 103), U = 3221.5, z = - 5.243, p < 0.001, 
r = 0.36, or hypertensive not on ACEIs group (Md = 132.25, n = 103), U = 2240.5, z = - 
7.631, p < 0.001, r = 0.53. The Mann-Whitney U test also indicated that grades of proctitis 
were higher in hypertensive not on ACEIs group (Md = 108.74, n=103) than that of non-
hypertensive not on ACEIs group (Md = 98.26, n = 103), U = 4765, z = 1.32, r = 0.09, but the 
difference was not significant. 
Table 3 shows that in the hypertensive on ACEIs group, the incidence of grades 0 and 1 
proctitis constituted 96.1% (n=98) whereas grades 2 and 3 proctitis were observed in 2.9% 
(n=3) and 1% (n=1): no grading of 4 or 5 proctitis was observed. By contrast, in the non-
hypertensive group grades 0 and 1 were observed only in 60.2% (n=62); however, grades 2, 3 
and 4 proctitis were found in 31.1% (n=32), 6.8% (n=7), 1.9% (n=2) respectively. In 
hypertensive and not on ACEIs group, grades 0 and 1 proctitis constituted 66% (n=68) 
whereas grades 2, 3 and 4 proctitis were seen in 24.3% (n=25), 7.8% (n=8) and 1.9% (n=2) 
respectively (Figure 1). 
The risk ratio of proctitis in hypertensive on ACEIs group was significantly lower than both 
hypertensive not on ACEIs group (RR 0.40, 95% CI, 0.30 – 0.53, p<0.001) and non-
hypertensive not on ACEIs group (RR 0.58, 95% CI, 0.44 – 0.77, p<0.001). Furthermore, risk 
ratio of proctitis in non-hypertensive not ACEIs group was significantly lower than 
hypertensive not on ACEIs (RR 0.74, 95% CI. 1.34 – 3.56, p<0.001). 
The onset of proctitis in hypertensive on ACEIs group was significantly different comparing 
to the two control groups (P<0.0001) (Figure 2). In regards to time to resolution of proctitis, 
It was observed that hypertensive on ACEIs group has significantly experienced shorter time 
of proctitis comparing to non-hypertensive not on ACEIs and hypertensive not on ACEIs 
groups (P<0,0001) (Figure 3).  
There was no significant differences were found between grades of proctitis and PSA level 
before treatment, follow-up, tumour stages or Gleason scores among the three groups. 
Discussion 
To our knowledge this is the first study to investigate the relationship between the use of 
ACEIs and the incidence, severity and duration of radiation induced proctitis. Based on the 
propensity score matched analysis and the EORTC and RTOG grading classification our 
findings suggest that the use of ACEIs during prostate radical radiotherapy is significantly 
associated with a low grade proctitis. Our findings are in keeping with other studies that have 
identified the beneficial effects of concurrent use of ACEIs on reducing radiation induced 
injuries including radiation induced pneumonitis (12), nephritis (29), GI tract toxicity (37) 
and brain injury (30). A key advantage of our study was that propensity score matched 
analysis and the EORTC and RTOG grading classification of toxicity was used. These two 
elements enhance the investigation of clinical signs and decrease the risk of bias in this study.  
Several studies have reported consistent results in the beneficial association between ACEIs 
and reduced risk of renal toxicity (20 – 29). Our findings observed that the intake of the 
ACEIs was significantly associated with reduced risk of radiation induced proctitis. 
Elsewhere, (22) did not report any association between ACEIs and reduced risk of radiation-
induced nephritis in a patient population of lung cancer patients.  
Our findings demonstrated that the time of onset of proctitis in hypertensive on ACEIs group 
was significantly different when compared to the two control groups (p<0.0001): with the 
majority of proctitis in ACEIs group took place in the first few weeks after radical 
radiotherapy. Furthermore, it was observed that hypertensive on ACEIs group had 
significantly faster resolution of proctitis (P<0.0001), with little difference between the two 
control groups. These findings suggest that ACEIs help to reduce the incidence of proctitis 
after radical radiotherapy as well as accelerating the resolution of proctitis. While the 
mechanism of action of ACEIs in reducing severity, incidence and resolution time of 
radiation induced proctitis are still unknown. Further studies are needed to inform the clinical 
recommendation of ACEIs administration in patients who are opting to have radical 
radiotherapy for prostate cancer, before and during treatment.  
One of the major limitations of the existing evidence-base is the reliability and validity of the 
measurement of proctitis (46, 47, 4 – 7). Specially, a range of studies have reported proctitis 
present or not present, and lacked the severity grading of proctitis (5 – 7), this is a major 
limitation to the existing data in this area. We implemented reliable and validated 
methodology, the European Organization for Research and Treatment of Cancer (EORTC) 
and the Radiation Therapy Oncology Group (RTOG) grading system of radiation proctitis 
(40, 41). The prevalence data of the rectal toxicity was derived from our comprehensive 
clinical databases. The level of inter-rater reliability between the observers using this 
classification system was found to have a substantial agreement with Kappa=0.809 with 
p<0.001. Our approach to grading the severity of proctitis has been verified by several studies 
(48 – 50, 36) and was found to be reliable and consistent.  
Rectal bleeding is one of the signs of radiation induced proctitis (51, 52, 4) which occurs due 
to mucosal friability and neovascular telangiectasias (53) with an average incidence up to 
75% (46, 47, 4 – 7). In the current study there were few patients (n=20) who had a history of 
haemorrhoids and were excluded from the analysis as the bleeding may have been secondary 
to the haemorrhoids and not proctitis.  
This study stratified into three groups by cancer stage, Gleason score, PSA, age, medication 
data and comorbidities. Based on EORTC and RTOG grading system the CHI square test 
demonstrated that low severity proctitis was statistically associated with the use of the ACEIs 
(P<0.001) after controlling age, stage, Gleason score and comorbidity. The current study 
observed that the Mann-Whitney U test indicated the severe grades of proctitis were higher in 
hypertensive patients not on ACEIs group than non-hypertensive patients group. 
Furthermore, the risk of proctitis was also significantly higher in hypertensive patients not on 
ACEIs group than non-hypertensive patients group. These findings suggest that non-
hypertensive patients experience lower grades of proctitis and were at lower risk of 
development of proctitis in comparison to those who were hypertensive not on ACEIs. 
Elsewhere, it has been suggested that hypertension reduces the risk of proctitis (32, 34, 36). 
This area is in its infancy and further research is needed to clarify the moderating and 
mediating pathways of hypertension and the risk of proctitis in this patient population. 
The use of multiple control groups is considered to be helpful in detection and balancing any 
hidden biases from any unobserved covariates and the estimation of the treatment effects 
become efficient (54). This study has used two control groups; the first was non-hypertensive 
not on ACEIs and the second was hypertensive not on ACEIs which was a strength to our 
study. 
To date, there is no clear evidence that demonstrates an association between proctitis and 
PSA, Gleason score or staging: this is in keeping with our findings.  
ACEIs are widely prescribed as a treatment for hypertension. ACEIs have reported to 
decrease radiation-induced injuries in renal, brain, GI tract (29, 30, 37) in different models, 
although the underlying main, moderating and mediating mechanisms are yet to be 
unexplored. Various proposed mechanisms include the pharmacological component; that all 
type I angiotensin receptor blockers, L-158,809 and ACEIs containing sulphydryl radical 
were more effective in protection the lung against lung fibrosis (13). These findings bring 
into clinical question that if the beneficial effect was due to the inhibition of the enzyme or 
the associated drugs such as antioxidant. Due to the limited number of participants who were 
on ACEIs (n=102), this study was not sufficiently powered to identify which type of the 
ACEIs was associated with low grades proctitis. Given the important clinical implications of 
our findings further investigations in larger sample are suggested. 
Conclusion  
In summary, this is the first study to examine the association of ACEIs on radiation induced 
rectal toxicity in men diagnosed with prostate cancer. Our findings confirm that patients who 
were on ACEIs were significantly less likely to have high grade proctitis after radical 
radiotherapy with neoadjuvant/adjuvant hormonal therapy. Besides, the intake of ACEIs were 
significantly associated with reduced risk of radiation induced proctitis as well as accelerating 
its resolution. ACEIs may offer several advantages in pelvic radiotherapy treatment but the 
moderation and mediating pathways are yet to be explored. Further clinical research is 
needed which in turn could decrease morbidity and increase the quality of life after 
radiotherapy. 
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Figure (1): Bar chart shows the distribution of the proctitis grading among hypertensive 
patients on ACEIs, non-hypertensive patients not on ACEIs and hypertensive not on ACEIs 
groups. 
Figure (2): Kaplan Meier curves show time to event between hypertensive patients on ACEIs, 
non-hypertensive patients not on ACEIs and hypertensive not on ACEIs groups over a 
median 6 years of follow-up. 
Figure (3): Cumulative incidence curve show time to resolution between hypertensive 
patients on ACEIs, non-hypertensive patients not on ACEIs and hypertensive not on ACEIs 
groups over a median 6 years of follow-up. 
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Figure (1): Bar chart shows the distribution of the proctitis grading among hypertensive patients on ACEIs, non-
hypertensive patients not on ACEIs and hypertensive not on ACEIs groups. 
 
 Figure (2): Kaplan Meier curves show time to event between hypertensive patients on ACEIs, non-
hypertensive patients not on ACEIs and hypertensive not on ACEIs groups over a median 6 years of 
follow-up. 
Figure (3): Cumulative incidence curve show time to resolution between hypertensive 
patients on ACEIs, non-hypertensive patients not on ACEIs and hypertensive not on 
ACEIs groups over a median 6 years of follow-up.  
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Grade Sign and symptoms  Overall management 
0 No symptoms  Does not require medication 
1 Minimal side effect such as urgency, 
occasional pain, superficial ulceration , < 
1cm2, mild stricture and occult rectal 
bleeding 
Treated as outpatient and does not 
require lifestyle adjustments.  
2 Intermittent urgency and pain, superficial 
ulceration >1cm2, intermittent rectal 
bleeding and moderate stricture  
Treated as outpatient and requires 
lifestyle adjustments. 
3 Persistent urgency, pain and bleeding, 
deep ulceration associated with sever 
stricture  
Needs hospital admission or minor 
surgical intervention associated radical 
adjustment of the lifestyle  
4 Sever urgency associated with sever 
uncontrollable pain, sever bleeding, 
perforation, fistula and complete 
obstruction 
Needs hospital admission or major 
surgical intervention 
5 Multi-organ failure, sepsis and death Fatal side effects 
Table 1: Grades of proctitis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Before propensity score matching After propensity score matching 
Covariate Group1 Group2 Group3 P Group1 Group2 Group3 P 
Number 183 428 206  102 103 103  
Age years         
Mean 68.93 66.49 69.54 <0.001 68.64 69.61 68.49 <0.313 
SD 5.87 7.29 6.08  5.31 5.59 6.11  
Range 52 – 90 49 – 90 53 – 89  55 – 79 56 – 83 52 – 89  
Follow-up 
(Y) 
        
Mean 2.98 3.38 3.11 <0.067 3.24 3.73 3.15 <0.074 
SD 1.95 2.10 2.10  1.90 2.10 1.82  
G.S    <0.502    <0.919 
2 – 6 28 82 44  14 13 14  
7 (3+4) 48 116 47  30 30 25  
7 (4+3) – 10 106 230 112  58 60 64  
Comorbidity    <0.001    <0.988 
Non 98 331 117  55 58 55  
         1 64 85 68  33 33 35  
       ≥ 2 21 12 21  14 12 13  
PSA (BT)    <0.225    <0.791 
≤10 73 155 72  42 42 45  
10 – 20  57 158 63  33 27 30  
>20  53 115 71  27 34 28  
Stages    <0.804    <0.796 
T0 1 3 1      
T1 14 42 22  7 9 6  
T2 84 171 93  45 38 41  
T3 80 200 81  50 56 56  
T4 4 12 6      
Grades        <0.001 
Grade 0 - - -  68 40 18  
Grade 1 - - -  30 22 50  
Grade 2 - - -  3 32 25  
Grade 3 - - -  1 7 8  
Grade 4 - - -  0 2 2  
Grade 5 - - -  0 0 0  
Table (2): Propensity score matching; group 1: hypertensive on ACEIs; Group 2: Non-
hypertensive not on ACEIs; Group 3: hypertensive not on ACEIs; GS: Gleason score; Y: 
years; BT: before treatment. 
 
 
 
 
 
 
  
 
 Grade  
Patients  Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 Total  
Group 1       
Count 68 30 3 1 0 102 
%within patients 66.7% 29.4% 2.9% 1% 0% 100% 
%within grade 54% 29.4% 5% 6.2% 0% 33.1% 
% of total 22.1% 9.7% 1% 0.3% 0% 33.1% 
Group 2       
Count 40 22 32 7 2 103 
%within patients 38.8% 21.4% 31.1% 6.8% 1.9% 100% 
%within grade 31.7% 21.6% 53.3% 43.8% 50% 33.4% 
% of total 13% 7.1% 10.4% 2.3% 0.6% 33.4% 
Group 3       
Count 18 50 25 8 2 103 
%within patients 17.5% 48.5% 24.3% 7.8% 1.9% 100% 
%within grade 14.3% 49% 41.7% 50% 50% 33.4% 
% of total 5.8% 16.2% 8.1% 2.6% 0.6% 33.4% 
Total        
Count 126 102 60 16 4 308 
%within patients 40.9% 33.1% 19.5% 5.2% 1.3% 100% 
%within grade 100% 100% 100% 100% 100% 100% 
% of total 40.9% 33.1% 19.5% 5.2% 1.3% 100% 
Table (3): Patients x grades cross-tabulation; Group 1: hypertensive on ACEIs; Group 2: non-
hypertensive not on ACEIs; Group 3: hypertensive not on ACEIs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
